萨库比特里尔/瓦尔萨坦对高血压心脏病的影响:REVERSE-LVH随机二期试验
Vivian Lee1, Mayank Dalakoti2, Qishi Zheng3
1National Heart Research Institute of Singapore, National Heart Centre Singapore, Singapore, Singapore.
Nature communications
|July 30, 2025
概括
与单独使用瓦尔沙坦相比,萨库比特里尔/瓦尔沙坦在患有高血压和左心室缩的患者中显著降低了间歇体积. 这表明,除了血压控制之外,心肌还可能有潜在的益处.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 医疗成像医学成像
背景情况:
- 扩散性间歇性纤维化与高血压心脏病的不良结果有关.
- 这种纤维化可能是可逆的治疗.
- 与瓦尔萨坦单独治疗相比,萨库比特里尔/瓦尔萨坦可能具有更强的抗纤维化作用.
研究的目的:
- 评估萨库比特里尔/瓦尔萨坦与瓦尔萨坦在患有基本高血压和左心室缩 (LVH) 的患者中的抗纤维化作用.
- 作为主要终点,评估间歇体积的变化.
主要方法:
- 在REVERSE-LVH试验中,78名患有基本高血压和LVH的患者随机获得了52周的萨库比特里尔/瓦尔萨坦或瓦尔萨坦.
- 使用心血管磁共振测量间歇体积.
- 血压,LV质量,心房体积和心脏生物标志物是次要终点.
主要成果:
- 萨库比特里尔/瓦尔萨坦比瓦尔萨坦更大程度地减少了间歇体积 (-5.2 ± 5.4 与 -2.5 ± 3.1 mL; P=0.006),尽管血压控制类似.
- 在LV质量,左心房体积和填充压力方面,观察到sacubitril/valsartan显著改善.
- 心脏生物标志物,包括NT-proBNP和高灵敏度的热血素T,也受到sacubitril/valsartan的有利影响.
结论:
- 萨库比特里尔/瓦尔萨坦在患有高血压的 LVH 患者中提供潜在的心肌益处,超出了降低血压的范围.
- 该药物的抗纤维性作用对管理高血压性心脏病有希望.
- 需要进行更大规模的临床试验来确认这些发现的临床意义.
更多相关视频
08:35Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.4K
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.6K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
510
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
510
01:30Heart Failure V: Medical Management
25
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
25
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
927
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
927
01:25Antihypertensive Drugs: Direct Renin Inhibitors
827
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
827
01:29Heart Failure II: Pathophysiology
44
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
44
01:22Heart Failure Drugs: Diuretics
495
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
495